This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignee: Allergan, Inc.. Active years: 2020.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2020
Title: **The Innovative Journey of Inventor Hao Hou**
Introduction
Hao Hou, an inventive mind located in Irvine, CA, holds a notable patent that contributes significantly to the field of ocular treatments. His dedication to innovation has led him to develop advanced formulations aimed at addressing common ocular conditions.
Latest Patents
Hao Hou is credited with a patent titled "Suspension compositions of cyclosporin A for subconjunctival and periocular injection." This patent outlines a pioneering approach to treating ocular conditions, utilizing suspension formulations containing cyclosporin A. The invention involves a sophisticated delivery system comprised of two components: one containing cyclosporin particles and the other incorporating additional necessary elements. This system allows for effective injection into the subconjunctival or periocular space, providing a targeted treatment for ailments such as dry eye disease.
Career Highlights
Hao Hou is currently associated with Allergan, Inc., a leading pharmaceutical company recognized for its commitment to developing innovative therapies for eye care and other medical fields. His contributions to ocular medicine through his patent reflect his expertise and dedication to improving patient outcomes.
Collaborations
Throughout his career, Hao has had the privilege of collaborating with notable colleagues including Anuradha V Gore and Chetan Pujara. These partnerships emphasize the importance of teamwork in driving innovation and advancing medical treatments, as they collectively work towards enhancing existing therapies and creating new solutions.
Conclusion
Hao Hou exemplifies the spirit of innovation in the medical field, particularly in ocular health. His patent showcases the potential of cyclosporin A in providing effective treatment options for patients suffering from ocular conditions. As he continues to work with talented professionals at Allergan, Inc., the future appears bright for further advancements in ocular therapeutics stemming from his groundbreaking work.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile